Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical)

重组抗HER2结构域Ⅱ人源化单抗（齐鲁制药）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRecombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical)
Drug Alias Name重组抗HER2结构域Ⅱ人源化单克隆抗体注射液（齐鲁）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A